This company listing is no longer active
BVX Stock Overview
A biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BiVictriX Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.14 |
| 52 Week Low | UK£0.07 |
| Beta | -0.73 |
| 11 Month Change | -23.08% |
| 3 Month Change | -18.37% |
| 1 Year Change | -28.57% |
| 33 Year Change | -50.00% |
| 5 Year Change | n/a |
| Change since IPO | -60.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| BVX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 33.3% | 2.5% | 2.2% |
| 1Y | -28.6% | -15.4% | 9.0% |
Return vs Industry: BVX underperformed the UK Biotechs industry which returned -21.4% over the past year.
Return vs Market: BVX underperformed the UK Market which returned 8.3% over the past year.
Price Volatility
| BVX volatility | |
|---|---|
| BVX Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BVX's share price has been volatile over the past 3 months.
Volatility Over Time: BVX's weekly volatility has increased from 7% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 17 | Tiffany Thorn | www.bivictrix.com |
BiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia.
BiVictriX Therapeutics plc Fundamentals Summary
| BVX fundamental statistics | |
|---|---|
| Market cap | UK£8.25m |
| Earnings (TTM) | -UK£2.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs BVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£2.67m |
| Earnings | -UK£2.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BVX perform over the long term?
See historical performance and comparison